Update on Alzheimer's disease
Authors:
- James R. BurkeJBJames R. Burke
- Joel C. MorgenlanderJMJoel C. Morgenlander
- 1 January 1999
- journal article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 106 (5) , 85-96
Abstract
In the past decade, significant progress has been made in the understanding and treatment of Alzheimer's disease. Modest success has been achieved using new drugs in treatment of mild symptoms of the disease. Vitamin E, estrogen, and NSAIDs may slow the progression of Alzheimer's disease, but their routine use is not without risk, and there is no evidence that these agents are effective in preventing the disease in asymptomatic people. With our increased understanding of the pathogenesis of Alzheimer's disease, it is likely that the next decade will see further refinement and development of treatment strategies to halt progression and possibly reduce the incidence of disease.Keywords
This publication has 10 references indexed in Scilit:
- Alzheimer's diseaseNeurology, 1998
- Apolipoprotein E and the CNS Response to InjuryJournal of Cerebral Blood Flow & Metabolism, 1998
- Estrogen Therapy in Postmenopausal WomenJAMA, 1998
- Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease”Neurobiology of Aging, 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's diseaseNeurology, 1997
- A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's DiseaseNew England Journal of Medicine, 1997
- Risk of Alzheimer's disease and duration of NSAID useNeurology, 1997
- Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's diseaseThe Lancet, 1996
- Clinical trial of indomethacin in Alzheimer's diseaseNeurology, 1993